INT8786

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1988
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 27
Total Number 28
Disease Relevance 12.81
Pain Relevance 4.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (ALDH7A1) small molecule metabolic process (ALDH7A1) cytoplasm (ALDH7A1)
cytosol (ALDH7A1) oxidoreductase activity (ALDH7A1) nucleus (ALDH7A1)
Anatomy Link Frequency
heart 3
ventricle 1
lower urinary tract 1
smooth muscle 1
artery 1
ALDH7A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
dexamethasone 44 99.92 Very High Very High Very High
cINOD 18 99.92 Very High Very High Very High
Inflammation 134 98.92 Very High Very High Very High
b2 receptor 116 97.64 Very High Very High Very High
Nicotine 384 96.28 Very High Very High Very High
adenocard 16 95.48 Very High Very High Very High
Angina 4 95.32 Very High Very High Very High
Inflammatory mediators 18 94.72 High High
cytokine 21 94.52 High High
addiction 3 93.52 High High
Disease Link Frequency Relevance Heat
Colon Cancer 5 99.86 Very High Very High Very High
Overactive Bladder 147 99.80 Very High Very High Very High
Myocardial Infarction 8 99.76 Very High Very High Very High
INFLAMMATION 165 99.72 Very High Very High Very High
Chronic Obstructive Pulmonary Disease 4 99.24 Very High Very High Very High
Reprotox - General 2 19 99.12 Very High Very High Very High
Respiratory Disease 4 99.08 Very High Very High Very High
Cardiovascular Disease 4 99.04 Very High Very High Very High
Peripheral Arterial Disease 2 98.72 Very High Very High Very High
Pulmonary Hypertension 82 98.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While selective inhibitors of the cGMP-inhibitable (cGi)-PDE isozyme have been approved for use in the acute treatment of heart failure, selective inhibitors of the cGMP-PDE have not been extensively explored as potential candidates for the treatment of cardiovascular diseases.
Negative_regulation (inhibitors) of PDE isozyme in heart associated with cardiovascular disease and myocardial infarction
1) Confidence 0.52 Published 1992 Journal Basic Res. Cardiol. Section Abstract Doc Link 1379794 Disease Relevance 0.19 Pain Relevance 0.07
Acute inotropic, lusitropic and arrhythmic effects of 5-HT on human ventricle become conspicuous after inhibition of phosphodiesterase (PDE) activity.
Negative_regulation (inhibition) of PDE in ventricle
2) Confidence 0.44 Published 2006 Journal Pharmacol. Ther. Section Abstract Doc Link 16960982 Disease Relevance 0.41 Pain Relevance 0.04
Recently, considerable attention has been focused on the potential use of selective inhibitors of cyclic nucleotide phosphodiesterases (PDEs) in the treatment of respiratory diseases as PDE isoenzymes may play an important role in the regulation of airway caliber and bronchial smooth muscle function [3].
Negative_regulation (inhibitors) of PDE in respiratory associated with respiratory disease
3) Confidence 0.42 Published 2005 Journal Cough Section Body Doc Link PMC1336741 Disease Relevance 0.79 Pain Relevance 0.04
Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?
Negative_regulation (inhibitors) of PDE associated with inflammation and cinod
4) Confidence 0.41 Published 1997 Journal Trends Pharmacol. Sci. Section Title Doc Link 9184477 Disease Relevance 0.46 Pain Relevance 0.27
Rolipram (4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone, ZK 62711) is a specific cAMP-PDE inhibitor.
Negative_regulation (inhibitor) of cAMP-PDE
5) Confidence 0.40 Published 1988 Journal Arzneimittelforschung Section Abstract Doc Link 3245853 Disease Relevance 0.07 Pain Relevance 0.17
While selective inhibitors of the cGMP-inhibitable (cGi)-PDE isozyme have been approved for use in the acute treatment of heart failure, selective inhibitors of the cGMP-PDE have not been extensively explored as potential candidates for the treatment of cardiovascular diseases.
Negative_regulation (inhibitors) of PDE in heart associated with cardiovascular disease and myocardial infarction
6) Confidence 0.38 Published 1992 Journal Basic Res. Cardiol. Section Abstract Doc Link 1379794 Disease Relevance 0.20 Pain Relevance 0.08
More potent selective inhibitors of the cGMP-PDE isozyme are needed to determine whether these pharmacological potentiators of EDRF and ANP will be useful in the therapy of angina, hypertension or heart failure.
Negative_regulation (inhibitors) of PDE isozyme in heart associated with angina, hypertension and myocardial infarction
7) Confidence 0.38 Published 1992 Journal Basic Res. Cardiol. Section Abstract Doc Link 1379794 Disease Relevance 0.48 Pain Relevance 0.10
Much of the evidence for the role that these isozymes have in the regulation of cellular processes has been generated through, or awaits, the identification of selective and potent PDE inhibitors.
Negative_regulation (inhibitors) of PDE
8) Confidence 0.34 Published 1992 Journal Basic Res. Cardiol. Section Abstract Doc Link 1379794 Disease Relevance 0.17 Pain Relevance 0.06
Cell biological studies provided circumstantial evidence that the mechanism by which these agents exert their antitumor effect should be attributed to inhibition of cyclic-GMP phosphodiesterase (cGMP-PDE).
Negative_regulation (inhibition) of PDE
9) Confidence 0.30 Published 2001 Journal Curr Opin Investig Drugs Section Abstract Doc Link 11569947 Disease Relevance 0.57 Pain Relevance 0.09
Cilostazol, an inhibitor of phosphodiesterase (PDE) type 3, is used clinically in peripheral artery disease.
Negative_regulation (inhibitor) of PDE in artery associated with peripheral arterial disease
10) Confidence 0.28 Published 2004 Journal J. Cereb. Blood Flow Metab. Section Abstract Doc Link 15625409 Disease Relevance 0.28 Pain Relevance 0.04
Subsequently, cumulative concentration-response curves were constructed for the selective PDE III inhibitors amrinone, milrinone and enoximone, and for theophylline and dipyridamole, with and without the addition of L-NAME 100 mumol litre-1 or glibenclamide 1 mumol litre-1.
Negative_regulation (inhibitors) of PDE
11) Confidence 0.27 Published 1996 Journal Br J Anaesth Section Abstract Doc Link 8672353 Disease Relevance 0 Pain Relevance 0.08
Previous studies have shown the effects of selective inhibition of PDE isozymes in inhibition of inflammatory cell function and relaxation of airway smooth muscle in asthmatic airways [3-9,21].
Negative_regulation (inhibition) of PDE in smooth muscle associated with inflammation and occupational lung diseases
12) Confidence 0.27 Published 2005 Journal Cough Section Body Doc Link PMC1336741 Disease Relevance 1.42 Pain Relevance 0.19
Modulation of intracellular key enzymes effecting second messenger metabolism, i.e. isoenzyme-selective PDE inhibition is a novel approach which possibly avoids the limitations of anticholinergic therapy in patients with lower urinary tract dysfunction.
Negative_regulation (inhibition) of PDE in lower urinary tract
13) Confidence 0.27 Published 2001 Journal World J Urol Section Abstract Doc Link 11760783 Disease Relevance 0.27 Pain Relevance 0.08
This study was conducted to evaluate whether inhibition of PDE subtype III can reduce bronchial responsiveness.
Negative_regulation (inhibition) of PDE
14) Confidence 0.22 Published 1995 Journal Am. J. Respir. Crit. Care Med. Section Abstract Doc Link 7812559 Disease Relevance 0 Pain Relevance 0
The present study indicates that concentrations of the NSAIDs celecoxib, indomethacin, and meclofenamic acid that inhibit growth of SW480 human colon cancer cells inhibit subcellular cGMP-phosphodiesterase (PDE) enzymatic activity and in intact cells induce a two- to threefold increase in intracellular levels of cGMP.
Negative_regulation (inhibit) of PDE in colon associated with colon cancer and cinod
15) Confidence 0.21 Published 2008 Journal Mol. Carcinog. Section Abstract Doc Link 18163459 Disease Relevance 0.43 Pain Relevance 0.25
Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED.
Negative_regulation (inhibitor) of PDE associated with reprotox - general 2
16) Confidence 0.18 Published 2003 Journal Expert Opin Pharmacother Section Abstract Doc Link 12614192 Disease Relevance 0.62 Pain Relevance 0.06
Nor did rofecoxib inhibit cGMP-PDE activity or cause other changes related to PKG activation in these cells.
Negative_regulation (inhibit) of PDE
17) Confidence 0.16 Published 2008 Journal Mol. Carcinog. Section Abstract Doc Link 18163459 Disease Relevance 0.34 Pain Relevance 0.26
As more clinical experience is reported for drugs like PDE inhibitors and BTX for the treatment of OAB, more practitioners are becoming comfortable offering off-label use of these agents, thus providing an alternative to antimuscarinic treatment.
Negative_regulation (inhibitors) of PDE associated with overactive bladder
18) Confidence 0.14 Published 2010 Journal F1000 Med Rep Section Body Doc Link PMC2948402 Disease Relevance 0.61 Pain Relevance 0
Sildenafil is a selective and potent inhibitor of PDE type 5 which specifically degrades cyclic guanosine monophosphate and is found in high concentrations in pulmonary arteries and the corpora cavernosum (Rabe et al 1994; Ahn et al 1991; Boolell et al 1996; Pauvert et al 2002; Pauvert et al 2003).
Negative_regulation (inhibitor) of PDE
19) Confidence 0.12 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.71 Pain Relevance 0.21
Though previous research failed to prove a bronchodilator effect of a PDE 3 and PDE 4 dual inhibitor, zardaverine, in patients with partially reversible chronic airway obstruction [7], others indicated the protective effect of selective PDE 3 and PDE 4 inhibitors [8,9].
Negative_regulation (effect) of PDE associated with chronic obstructive pulmonary disease
20) Confidence 0.12 Published 2005 Journal Cough Section Body Doc Link PMC1336741 Disease Relevance 0.63 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox